We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
National Vision (EYE) Q1 Earnings Top Estimates, View Up
Read MoreHide Full Article
National Vision Holdings Inc. (EYE - Free Report) delivered adjusted earnings per share (EPS) of 48 cents for the first quarter of 2021, a significant 72.8% rise from the prior-year quarter. The figure exceeded the Zacks Consensus Estimate by 45.5%.
The adjustment excludes the impact of certain non-recurring charges like asset impairment, amortization of acquisition intangibles and stock compensation expenses, among others.
GAAP EPS for the quarter was 48 cents as well compared with 12 cents in the year-earlier quarter.
Revenues in Detail
Revenues in the first quarter totaled $534.2 million, beating the Zacks Consensus Estimate by 3.1%. The top line improved 13.7% from the year-ago number. The company noted that net revenue growth was negatively impacted by 7.4% due to the timing of unearned revenues.
In the first quarter, comparable store sales growth was 18.2% whereas adjusted comparable store sales growth was 35.8%.
National Vision opened 25 new stores in first-quarter 2021 and closed one to reach 1,230 stores at the end of the quarter. Overall, store count grew 4.9% year over year.
Margins
Gross profit in the reported quarter was $309.5 million, up 23.2% from the prior-year quarter. Gross margin of 57.9% expanded 447 basis points (bps).
Meanwhile, selling, general and administrative expenses increased 15.4% to $223.6 million. Adjusted operating margin was 16.1%, implying a 386-bps expansion year over year.
Financial Position
National Vision exited the first quarter of 2021 with cash and cash equivalents of $453.7 million compared with $373.9 million at the end of the prior quarter.
National Vision Holdings, Inc. Price, Consensus and EPS Surprise
Cumulative net cash flow from operating activities at the end of the first quarter was $97.7 million compared with $86.1 million a year ago.
2021 Outlook Lifted
National Vision updated its 2021 guidance.
Net revenues are expected in the range of $1.975 - $2.025 billion (an improvement from the previously-announced view of $1.93-$1.98 billion). The Zacks Consensus Estimate for the same is currently pegged at $1.96 billion.
Adjusted EPS estimate guidance too has been raised to the band of $1.07-$1.12 (88-93 cents). The Zacks Consensus Estimate for the same is currently pegged at 90 cents.
Adjusted comparable store sales growth is expected to be within 16-19% (13-16%).
Our Take
National Vision reported better-than-expected first-quarter results. The company witnessed comparable growth on increased customer transaction in the quarter. According to the company, increased demand for low-cost eye exams, glasses and contact lenses contributed to making an outstanding first quarter. Expansion of both margins bodes well.
Despite the pandemic, based on the solid year-to-date momentum, the company has raised its full year guidance.
Zacks Rank and Key Picks
National Vision currently carries a Zacks Rank #2 (Buy).
Boston Scientific reported first-quarter 2021 adjusted EPS of 37 cents, beating the Zacks Consensus Estimate by 23.3%. Net revenues of $2.75 billion outpaced the consensus estimate by 5.3%.
Illumina reported first-quarter 2021 adjusted EPS of $1.89, beating the Zacks Consensus Estimate by 38.9%. Revenues of $1.09 billion outpaced the consensus estimate of $1.08 billion.
HCA Healthcare reported first-quarter 2021 adjusted EPS of $4.14, surpassing the Zacks Consensus Estimate by 23.6%. Net revenues of $14 billion exceeded the Zacks Consensus Estimate by 2.2%.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Image: Bigstock
National Vision (EYE) Q1 Earnings Top Estimates, View Up
National Vision Holdings Inc. (EYE - Free Report) delivered adjusted earnings per share (EPS) of 48 cents for the first quarter of 2021, a significant 72.8% rise from the prior-year quarter. The figure exceeded the Zacks Consensus Estimate by 45.5%.
The adjustment excludes the impact of certain non-recurring charges like asset impairment, amortization of acquisition intangibles and stock compensation expenses, among others.
GAAP EPS for the quarter was 48 cents as well compared with 12 cents in the year-earlier quarter.
Revenues in Detail
Revenues in the first quarter totaled $534.2 million, beating the Zacks Consensus Estimate by 3.1%. The top line improved 13.7% from the year-ago number. The company noted that net revenue growth was negatively impacted by 7.4% due to the timing of unearned revenues.
In the first quarter, comparable store sales growth was 18.2% whereas adjusted comparable store sales growth was 35.8%.
National Vision opened 25 new stores in first-quarter 2021 and closed one to reach 1,230 stores at the end of the quarter. Overall, store count grew 4.9% year over year.
Margins
Gross profit in the reported quarter was $309.5 million, up 23.2% from the prior-year quarter. Gross margin of 57.9% expanded 447 basis points (bps).
Meanwhile, selling, general and administrative expenses increased 15.4% to $223.6 million. Adjusted operating margin was 16.1%, implying a 386-bps expansion year over year.
Financial Position
National Vision exited the first quarter of 2021 with cash and cash equivalents of $453.7 million compared with $373.9 million at the end of the prior quarter.
National Vision Holdings, Inc. Price, Consensus and EPS Surprise
National Vision Holdings, Inc. price-consensus-eps-surprise-chart | National Vision Holdings, Inc. Quote
Cumulative net cash flow from operating activities at the end of the first quarter was $97.7 million compared with $86.1 million a year ago.
2021 Outlook Lifted
National Vision updated its 2021 guidance.
Net revenues are expected in the range of $1.975 - $2.025 billion (an improvement from the previously-announced view of $1.93-$1.98 billion). The Zacks Consensus Estimate for the same is currently pegged at $1.96 billion.
Adjusted EPS estimate guidance too has been raised to the band of $1.07-$1.12 (88-93 cents). The Zacks Consensus Estimate for the same is currently pegged at 90 cents.
Adjusted comparable store sales growth is expected to be within 16-19% (13-16%).
Our Take
National Vision reported better-than-expected first-quarter results. The company witnessed comparable growth on increased customer transaction in the quarter. According to the company, increased demand for low-cost eye exams, glasses and contact lenses contributed to making an outstanding first quarter. Expansion of both margins bodes well.
Despite the pandemic, based on the solid year-to-date momentum, the company has raised its full year guidance.
Zacks Rank and Key Picks
National Vision currently carries a Zacks Rank #2 (Buy).
A few other top-ranked stocks in the broader medical space are Boston Scientific Corporation (BSX - Free Report) , Illumina, Inc. (ILMN - Free Report) and HCA Healthcare, Inc. (HCA - Free Report) . All three stocks carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific reported first-quarter 2021 adjusted EPS of 37 cents, beating the Zacks Consensus Estimate by 23.3%. Net revenues of $2.75 billion outpaced the consensus estimate by 5.3%.
Illumina reported first-quarter 2021 adjusted EPS of $1.89, beating the Zacks Consensus Estimate by 38.9%. Revenues of $1.09 billion outpaced the consensus estimate of $1.08 billion.
HCA Healthcare reported first-quarter 2021 adjusted EPS of $4.14, surpassing the Zacks Consensus Estimate by 23.6%. Net revenues of $14 billion exceeded the Zacks Consensus Estimate by 2.2%.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>